A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials

摘要: We conducted a meta-analysis of pharmacogenomic substudies three randomized trials in patients with decompensated heart failure (HF) that were led by National Heart Lung and Blood Institute (NHLBI)-funded HF Network to test the hypothesis candidate genes modulate net fluid loss weight change treated furosemide-based diuretic regimen. Although none genetic variants previously shown effects loop diuretics healthy individuals associated after 72 h treatment, set rare APOL1 gene, which codes for apolipoprotein L1 (P=0.0005 random model), was this end point. Moreover, common variant multidrug resistance protein-4 coding gene (ABCC4, rs17268282) furosemide use (P=0.0001). Our results suggest both response regimen HF.